Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Adv Exp Med Biol. 2020;1177:37-73. doi: 10.1007/978-981-15-2517-9_2.
In this chapter, we focus on evidences in current guidelines for treatment of coronary artery disease (CAD). In Part 1, diet and lifestyle management is discussed, which plays an important role in CAD risk control, including forming healthy dietary pattern, maintaining proper body weight, physical exercise, smoking cessation, and so on. Part 2 elaborated on revascularization strategies and medical treatments in patients presenting with acute coronary syndrome (ACS), including specific AHA and ESC guidelines on ST elevation myocardial infarction (STEMI) and non-ST elevation ACS (NSTE-ACS). Part 3 discussed chronic stable coronary artery disease (SCAD), the treatment objective of which is a combination of both symptomatic and prognostic improvement. Yet many of the recommendations for SCAD are expert-based rather than evidence-based. Initial medical treatment is safe and beneficial for most patients. While cumulating studies have focused on optimizing pharmacological therapy (referring to nitrates, beta-blockers, calcium channel blockers, antiplatelet agents, ACEI/ARB, statins, etc.), education, habitual modification, and social support matters a lot for reducing cardiac morbidity and mortality. Patients with moderate-to-severe symptoms and complex lesions should be considered for revascularization. But practical management of revascularization shall take individual characteristics, preference, and compliance into consideration as well.
在这一章中,我们重点介绍当前冠心病治疗指南中的证据。在第 1 部分中,讨论了饮食和生活方式管理,这在冠心病风险控制中起着重要作用,包括形成健康的饮食模式、保持适当的体重、体育锻炼、戒烟等。第 2 部分详细阐述了急性冠状动脉综合征(ACS)患者的血运重建策略和药物治疗,包括特定的 AHA 和 ESC 指南对 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型 ACS(NSTE-ACS)的指南。第 3 部分讨论了慢性稳定型冠状动脉疾病(SCAD),其治疗目标是改善症状和预后。然而,SCAD 的许多建议都是基于专家意见,而不是基于证据。初始药物治疗对大多数患者是安全且有益的。虽然累积研究集中在优化药物治疗(包括硝酸酯类、β受体阻滞剂、钙通道阻滞剂、抗血小板药物、ACEI/ARB、他汀类药物等),但教育、习惯改变和社会支持对于降低心脏发病率和死亡率非常重要。对于有中重度症状和复杂病变的患者,应考虑血运重建。但血运重建的实际管理还应考虑到个体特征、偏好和依从性。